One Broadway, 14th floor
9 articles with Nuvalent
During the past two years, fundraising and investment in biotechnology have reached record levels.
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported recent pipeline and business highlights and second quarter 2021 financial results.
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its upsized initial public offering of 11,212,500 shares of common stock,
Nuvalent, Inc. announced the pricing of its initial public offering of 9,750,000 shares of common stock, consisting of 9,150,000 shares of Class A common stock and 600,000 shares of Class B common stock, each at a price to the public of $17.00 per share.
Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Funding to Advance Parallel Lead Programs in ROS1-positive and ALK-positive NSCLC to Phase 1/2 Clinical Trials and Expand Discovery Research Pipeline
2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.